Pacira Biosciences Inc. acquires Flexion Therapeutics Inc. and with it, Zilretta, a treatment for OA knee pain
The CVR is payable (subject to certain terms and conditions) in the event certain sales and/or regulatory milestones are achieved. The transaction was unanimously approved by the board of directors of each of Pacira and Flexion. Flexion is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis (OA), postsurgical pain and low back pain. Approved in 2017, Flexion’s lead product, Zilretta (triamcinolone acetonide extended-release injectable suspension) is the first and only FDA-approved treatment for OA knee pain utilizing extended-release microsphere technology.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins